Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On April 16, 2026, Tiziana Life Sciences reported positive preclinical data from independent academic collaborators showing that intranasal anti-CD3 antibody treatment reduced neuroinflammation and improved cognition in a mouse model of Long COVID. The bioRxiv study, which evaluated a nasal anti-CD3 monoclonal antibody resembling Tiziana’s foralumab, also found increased regulatory T cells in the brain, restored hippocampal neurogenesis and reversal of “brain fog”-like deficits, reinforcing the rationale for Tiziana’s intranasal foralumab programs and potentially bolstering its positioning in post-viral neuroinflammatory indications.
The work, led by researchers at Yale University and Brigham and Women’s Hospital, used a mild respiratory SARS-CoV-2 mouse model and complementary human data showing reduced circulating Tregs in Long COVID patients with neurological symptoms. Executives said the findings validate the mechanistic foundation for ongoing clinical efforts in multiple sclerosis and other neurodegenerative diseases, and may support expansion into Long COVID “brain fog,” adding momentum to Tiziana’s broader intranasal immunotherapy platform.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on immunotherapy delivered through alternative routes, particularly intranasal administration. Its lead asset, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, targets neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis, MSA, Alzheimer’s disease and ALS.
Average Trading Volume: 174,625
Technical Sentiment Signal: Hold
Current Market Cap: $158.1M
For an in-depth examination of TLSA stock, go to TipRanks’ Overview page.
